In the News

Prostate Cancer Survivor, John Sharp is on an Epic Journey through the Great Lakes region and Canada on his Ural Motorcycle to spread the word on Prostate Cancer Awareness.

fighting one man

Read More

Millenium Blend is committed to prostate cancer awareness and a lifetime of optimal health. Order today to receive an exclusive 30% discount with an automatic 10% donation to PCEC by visiting their website and entering PCEC for the coupon code upon check out!

Get More Information

Watch this important video presentation from Dr. E. David Crawford on improving survival in Advanced Prostate Cancer and the changing role of the Urologist.

Dr. David Crawford appears on UroToday and Speaks on Improving Survival in Advanced Prostate Cancer: The Changing Role or the Urologist. 

View Dr. David Crawford on Uro Today

 

Wendy Poage discusses her role as a Patient Advocate at the American Society of Clinical Oncolgoy - Genitourinary meeting during and interview with Cancer.Net expert Dr. Robert Miller.  Listen to hear more on the discussion on exciting advances from the meeting and the role of advocacy in research.

Listen to the CancerNet podcast Here

The Prostate Cancer Roundtable commends Congressmen Marsha Blackburn and John Barrow for their introduction of H.R. 5998, the USPSTF Transparency and Accountability Act of 2012.  The bill is designed to reform a process whose flaws were highlighted by the recent prostate cancer screening recommendation process. The Task Force failed to consider input from patient representatives and medical specialists. The Task Force also failed to reach out to other federal agencies conducting research on prostate cancer screening, and heavily relied on a study that has been universally criticized as being critically flawed.

"Patient representatives and medical specialists and stakeholders in the topic area under study need to be a part of the process of developing recommendations. This legislation will establish an advisory board to do just that," stated Merel Nissenberg, President of the National Alliance of State Prostate Cancer Coalitions.

"The recent prostate cancer screening recommendation by the Task Force largely ignored the benefits of screening for men known to be at high risk, including African American men, men with a family history of prostate cancer, veterans exposed to Agent Orange, and men with an above- average baseline PSA in their 40s. This legislation will require the Task Force to provide greater consideration of high-risk populations," stated Thomas Farrington, President of the Prostate Health Education Network.

The above statement has been issued on behalf of and endorsed by the  Prostate Cancer Roundtable member organizations including the Prostate Conditions Education Council.

 

The Robert J. Krane Prize

Best Clinical Paper of 2011 

British Journal of Urology International

 

Prostate danger zone study wins international best paper!

 

A high level of prostate-specific antigen (PSA) predicts prostate cancer – about 30 percent of men with PSA over 4.0ng/ml have the disease. And until recently, below 4.0ng/ml was considered fairly safe. A University of Colorado Cancer Center paper shows that even at PSA levels between 1.5-4.0ng/ml, a man's chance of having prostate cancer increases 15-fold. 

 

Chosen as the year's top publication in the British Journal of Urology International.

 

"We call this the 'early warning PSA zone'," says E. David Crawford, MD, of the Prostate Conditions Education Council,  the University of Colorado Cancer Center, and the study's lead author.

 

Specifically, Crawford's study examined data from at 21,502 men over age 40 who were found to have between 0 and 4.0ng/ml PSA, and who were then tested again at least four years later. Which of these men testing in the "normal" PSA range were later found to have prostate cancer? Well, 7.85 percent of men with PSA levels between 1.5-4.0ng/ml compared to only 0.51 percent of men below this concentration were later found to have the disease. The risk in the "normal" population was even a bit higher for African American males, who were found to have a 19-fold increase in prostate cancer rates as PSA passed 1.5ng/ml.

"This is a robust finding," Crawford says, "and it has the potential to make doctors and other caregivers rethink how we interpret PSA levels.”

 

Crawford will accept the Robert J. Krane Prize for the Best Clinical Paper of 2011 at the annual meeting of the American Urological Association, May 20, 2012 in Atlanta, Georgia.

 

 

 

NEW SCREENING OPTION COMING FOR PROSTATE CANCER

Denver, CO -The Prostate Conditions Education Council (PCEC), a national organization committed to men’s health and a leader in prostate cancer screening, released the following statement in response to the Premarket Approval (PMA) from the United States Food and Drug Administration (FDA) for Beckman Coulter’s Prostate Health Index (phi).  The statement is attributed to PCEC President, Wendy Poage, MHA.

“Today’s announcement of Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for Beckman Coulter’s Prostate Health Index (phi) represents a promising and exciting advancement for men and their physicians.  As the debate around prostate cancer screening continues, the PCEC welcomes the addition of new screening tools that offer men options that improve upon current screening methods.  Our hope is that new options like this test will help to mitigate concerns around screening by reducing the number of unnecessary biopsies, cutting back on the over diagnosis and treatment of prostate cancer, and lowering costs associated with prostate cancer detection.  

Prostate cancer remains the second leading cause of cancer death among American men.[i]  Prostate cancer can be an aggressive disease that is most successfully treated when it is detected early on.  The PCEC believes all men should be informed about the disease and their options for testing.  Each year, the PCEC holds Prostate Cancer Awareness Week, dedicated to offering free or low-cost screenings for more than 125,000 men across the U.S. and internationally.  Since the first PCAW in 1989, the program has helped to screen nearly five million men in the U.S., and this number continues to grow each year both at home and internationally.”